Advanced Filters
noise
Found 296 clinical trials
M Minghua Ge

Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma

This is a real world study aiming to observe the efficacy and safety of Anlotinib capsules in patients with advanced medullary thyroid carcinoma, and to summarize the treatment experience in a broad population of patients.

18 - 75 years of age All Phase 4
H Harry Quon, M.D.

Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer

The goal of this study is to evaluate combined radioactive iodine (RAI, 131-I) and external beam radiotherapy (XRT) to optimize the radiation dose delivered to treat well differentiated thyroid cancers (DTC) with iodine-avid metastases. The investigators hypothesize that precise dosimetric planning will permit this combined RAI-XRT radiotherapeutic approach to be …

18 - 85 years of age All Phase 1
P Peng juan

AI Models to Predict Thyroid Cartilage Invasion in Laryngeal Carcinoma

This retrospective study was to develop and verify CT-based AI model to preoperatively predict the thyroid cartilage invasion of laryngeal cancer patients, so as to provide more accurate diagnosis and treatment basis for clinicians. In addition, the researchers investigated the prediction of survival outcomes of patients by the above optimal …

18 - 81 years of age All Phase N/A
S SİNEM KESER, MD

Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease

This retrospective observational study aims to evaluate the relationship between systemic inflammatory parameters, thyroid autoimmunity markers, and neuroretinal structures in patients with Graves disease. Medical records of patients diagnosed with Graves disease and healthy control subjects evaluated at Elazığ Fethi Sekin City Hospital between August 2018 and January 2026 will …

18 years of age All Phase N/A
E Elizabeth G. Grubbs

Cultural Adaptation of an Educational Tool in Medullary Thyroid Cancer

To find good information about medullary thyroid cancer that is easy to understand and reliable, so researchers aim to design some new educational materials to help.

18 years of age All Phase N/A
G Giannis Koutelidakis, Professor of Surgery

The Impact of Immersive Virtual Reality Training in Thyroid Surgery

Up to this date, there have been no reports on virtual reality (VR) training in thyroid surgery. The purpose of this study is to determine the impact of VR training in residents' education. Investigators intend to include general surgery residents in the trial, subgrouped in a VR training group and …

years of age All Phase N/A
C Chin-Sung Kuo, MD, PhD

Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease

The goal of this clinical trial is to learn whether statin therapy and vitamin D supplementation can modify disease activity in patients with active thyroid eye disease. The study will also evaluate the safety of these treatments. The main questions it aims to answer are: Does statin therapy change disease …

20 years of age All Phase N/A

Natural History Study of Children and Adults With Medullary Thyroid Cancer

Background \- Medullary thyroid cancer (MTC) is a rare cancer of the thyroid gland. In children and adults, it is often part of a condition called Multiple Endocrine Neoplasia 2 (MEN2). MEN2 is usually caused by a genetic mutation, and it can cause a number of problems in addition to …

4 years of age All Phase N/A
E Ernest Dzhelialov

Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer

This pilot phase 2 study evaluate the effectiveness and safety of pembrolizumab and lenvatinib in patients with anaplastic thyroid cancer. Patients with anaplastic thyroid cancer who are treatment-naive (BRAF-negative) and who were previously treated with chemptherapy or targeted therapy are scheduled to undergo pembrolizumab and lenvatinib and evaluate the outcomes …

18 years of age All Phase 2
D Dongmei Ji, doctor

Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer

This phase II trial evaluates Tunlametinib (MEK inhibitor) ± PD-1 in NRAS-mutant advanced thyroid cancer. Key Objectives: Assess efficacy (ORR by RECIST v1.1) Evaluate safety profiles Study Design: Single-arm, single-center 4 cohorts based on: Histology (differentiated vs. poorly/undifferentiated) Prior therapy status Treatment Cohorts 1-2: Tunlametinib monotherapy (12mg BID) Cohorts 3-4: …

18 years of age All Phase 2

Simplify language using AI